1Young RC;Decker DG;Wharton JT.Staging laparotomy in early ovarian cancer,1983.
2Kehoe S;Selman T.Tumour markers in ovarian cancer,2001.
3Verheijen RH;von Mensdorff-Pouilly S;van Kamp GJ.CA125: fundamental and clinical aspects[J],1999(2).
4Jacobs I;Davies AP;Bridges J.Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography[J],1993.
5Helzlsouer KJ;Bush TL;Alberg AJ.Prospective study of serum CA- 125 levels as markers of ovarian cancer,1993.
6Skates SJ;Xu FJ;Yu YH.Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers[J],1995.
7Xu Y;Shen Z;Wiper DW.Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers[J],1998.
8Udagawa Y;Aoki D;Ito K.Clinical characteristics of a newly developed ovarian tumour marker,galactosyltransferase associated with tumour (GAT),1998(34).
9Lambert-Messerlian GM;Steinhoff M;ZHENG W.Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer[J],1997.
10Schutter EM;Sohn C;Kristen P.Estimation of probability of malignancy using a logistic model combining physical examination,ultrasound,serum CA 125,and serum CA 72-4 in postmenopausal women with a pelvic mass:an international multicenter study[J],1998.
